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ABSTRACT

Objective: The objective of this systematic review is to determine how well leukotriene
inhibitors/modifiers reduce symptoms associated with nasal polyps.

Study Design: The studies included in this review are three randomized controlled trials.

Data Source: The three RCTs in this review were obtained by performing a PubMed search using
the keywords “nasal polyp”, “leukotriene”, and “Montelukast”. All articles were published in
English and in peer-reviewed journals.

Outcomes Measured: The three studies determine whether there was significant improvement of
symptoms in patients with nasal polyps who were treated adjunctively with leukotriene
inhibitors/modifiers. The symptoms were measured before and after the treatments using three
different symptom score guidelines.

Results: Patients who were diagnosed with chronic rhinosinusitis with nasal polyposis who were
given Montelukast (leukotriene inhibitor) as adjunctive therapy demonstrated statistically
significant reduction in symptoms, p<0.05. In all three studies, Wu et al10, Yelverton et al11, Suri
et al12 the symptom scores decreased significantly in comparison to patients who received no
Montelukast adjunctive therapy.

Conclusions: Based on the systematic review of the three randomized controlled trials, one can
decisively say that leukotriene inhibitors/modifiers (Montelukast) can reduce the symptoms
associated with the presence of nasal polyps. All three studies verified statistically significant
reduction in symptoms compared to the control groups.
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INTRODUCTION
Nasal polyps are noncancerous growths inside the nose or sinuses which can cause or
exacerbate a variety of symptoms.1 Their development can be linked to chronic inflammation,
autonomic nervous system dysfunction, and genetic predisposition.1 However, a definitive
pathogenesis of these polyps has yet to be discovered.1 Theories state that nasal polyps arise
from conditions leading to chronic inflammation of the nasal mucosa such as allergic states or
recurrent infection.1 The nasal polyps most commonly discussed are benign semitransparent
lesions which arise from the mucosa of the nasal cavity or from the paranasal sinuses.1 They are
usually found at the outflow tract of the sinuses and can result in symptoms such as rhinorrhea,
congestion, postnasal drip, anosmia, facial pain or headache, or snoring.1 Children with chronic
sinusitis, cystic fibrosis, allergic rhinitis, and allergic fungal sinusitis are more likely to have
multiple nasal polyps. 1

Nasal polyps are relevant to the physician assistant practice because they affect 1-4% of
adults and 0.1% of children in the United States.1 Patients affected with the symptoms of nasal
polyps will first present to a primary care practice, a field containing a large portion of all
physician assistants.1 They have increased occurrence in men and usually manifest after 20 years
of age, if they are benign.1 The incidence of cystic fibrosis patients with nasal polyps ranges
between 6-48%.1 The polyps obstruct the outflow tract of the sinuses leading to recurrent sinus
infections or allergic rhinitis.1 Nasal polyps are relevant to patients because those affected will
have multiple doctor appointments and days of work/school missed a year.1
Nasal polyps themselves do not require treatment.2 The infections which result because
of their obstruction is what costs the most.2 It is estimated that sinusitis costs the U.S. $6 billion
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every year to treat.2 Therefore if 1-4% of the population has nasal polyps, recurrent sinusitis
treatment could cost over $240 million a year.2 Patients with nasal polyps will have recurrent
sinusitis which ends up costing them even more.2 Recurrent outpatient visits lead to
accumulation of various medications and antibiotics which, without health insurance, can
become costly.1 Once the decision is made to remove the nasal polyps through endoscopic nasal
surgery, it can cost the patient thousands depending where the patient receives surgery.2
Chronic sinusitis is responsible for 16 million outpatient visits a year.3 Therefore, it can
be estimated that patients with symptomatic nasal polyps lead to 160,000-640,000 outpatient
visits a year.3 This results in countless hours lost and work days missed.3 The diagnosis of nasal
polyps is not always easy especially if they cannot be visualized on physical exam.3 Due to this,
patients come back for more outpatient visits for recurrent symptoms.3 If a patient decides to
undergo endoscopic sinus surgery to remove the nasal polyps, they could end up missing up to a
week of work.3
The exact cause or pathogenesis behind nasal polyps is unknown.4 However, most
theories reveal they are caused by a reaction to allergies, inflammation, and rarely, cystic
fibrosis.4 Nasal polyp formation usually takes place in the middle meatus.4 The meatus becomes
edematous due to fluid collection which leads to a polypoidal change.4 This change develops the
new sessile polyps.4 They become pedunculated and obstructive after excessive sneezing,
rhinorrhea, and time, due to gravity.4 Nasal polyps present most commonly in patients with
chronic rhinosinusitis but are also associated with other diseases such as asthma, aspirinexacerbated respiratory disease, cystic fibrosis, allergic fungal sinusitis, Kartagener’s syndrome,
Young’s syndrome, eosinophilic granulomatosis with polyangiitis, and nasal mastocytosis.5
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The methods used to treat nasal polyps are aimed at reducing the symptoms that they
exacerbate or the underlying inflammation.6,7 For example, one of the most commonly used
medications for treating the intranasal inflammation are topical nasal steroid sprays with
triamcinolone, budesonide, or fluticasone.6,7 If the exacerbation is severe, oral corticosteroids
may also be given such as oral prednisolone, methylprednisolone, or dexamethasone.6,7 To
relieve any itching or rhinorrhea a medical provider could prescribe any antihistamine such as
diphenhydramine, cetirizine, loratadine, or fexofenadine.6,7 To relieve symptoms such as sinus
congestion, decongestants such as phenylephrine or pseudoephedrine can be prescribed.6,7 Some
medical providers will prescribe cromolyn sodium for a patient with excessive inflammation for
which intranasal steroid treatment failed or is contraindicated.6,7 Leukotriene inhibitors/modifiers
such as Zafirlukast, Montelukast, or zileuton have recently become an adjuvant medication for
nasal polyp associated symptoms, and are the medical therapy in question in this review.8
Finally, if the symptoms are persistent and cannot be controlled, patients have an option to
undergo endoscopic sinus surgery or polypectomy.8
Patients with nasal polyp obstruction have difficulty finding the right medications to
continually treat their chronic symptoms. 9 Leukotriene inhibitors or modifiers are an adjunct
medication option for patients with chronic sinusitis with nasal polyposis. 9 Leukotrienes act to
sustain inflammatory reactions in the body such as asthma and allergies. 9 Leukotriene receptor
antagonists such as Zafirlukast or Montelukast can bind to the receptors to block the
inflammatory response leukotrienes perpetuate. 9 The blocked inflammatory response will reduce
the symptoms identified as being problematic with nasal polyps.9
OBJECTIVE
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The objective of this systematic review is to determine whether leukotriene
inhibitors/modifiers reduce symptoms associated with nasal polyps.
METHODS
The three studies included in this review are all randomized control trials. 10-12 The
studies were included because all patients were 18 years old or older, had been diagnosed with
chronic rhinosinusitis with nasal polyposis, and were willing to participate in any imaging
studies. 10-12 The studies were also included because they compared leukotriene inhibitors as
adjunctive medical therapy versus a steroid based medical regimen that excluded leukotriene
inhibitors.10-12 Patients excluded from these studies were ones who used oral/nasal steroid or
immune-modulators in the past 4 weeks prior to the study. 10-12 Patients were also excluded if
they had a history of acute infection, antrochoanal polyps, cystic fibrosis, fungal sinusitis, or
gastroesophageal reflux disease. 10-12 Patients who had only unilateral polyps or history of
sensitivity to protocol drug regimen were also excluded.10-12 Suri et al also excluded those with
recent nasal surgery.12
All three studies included symptom score reports proving significance to the patient
population. 10-12 The articles were published in English, in peer-reviewed journals, and were
investigated for inclusion in this review, by the author. Keywords for the PubMed and
EBSCOhost search were “leukotriene”, “nasal polyp”, and “Montelukast”. 10-12 From that
selection, the three articles included were chosen based on relevance to topic and outcomes
which mattered to patients. 10-12 The three articles included were all published after 2014 and
excluded patients under18 years old, patients with a contraindication to steroid intake, or patients
with a sensitivity reaction to any of the medication regimen. 10-12 All statistics reported for the
articles used p-value. 10-12 The demographic and characteristics are included below. 10-12
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Table of demographics and characteristics of included studies (Table 1)
Study

RCT

31

Age
(yrs)
25-62

Yelverton, RCT
(2016)11

27

18-76

Patients >17
with chronic
sinusitis
with NPs
who had no
Montelukast
therapy for
at least 1
month.

Patients with
cystic fibrosis, a
fungal ball, or on
a tapered
prednisone
regimen

0

Post
endoscopic
sinus surgery
regimen with
added on
Montelukast
10mg

Suri,
(2015)12

40

24-58

Patients
who agreed
to undergo
an ENT
examination
and CT scan
of paranasal
sinuses, and
nasal
endoscopy

Patients who had
only unilateral
polyps, current
steroid intake,
nasal surgery, or
history of
sensitivity to
protocol drug
regimen

0

Oral steroid
prednisolone
35mg with
nasal steroid
budesonide
(2 metered
doses) with
orally
administered
Montelukast
10mg

Wu,
(2016) 10

Type

RCT

# Pts

Inclusion
Criteria
Patients
≥18 years
old with the
diagnosis of
chronic
sinusitis
with NPs
based on
history,
nasal
endoscopy,
and CT scan

Exclusion
W/D
Criteria
Patients who
0
used oral/nasal
steroid or
immunemodulators in the
past 4 weeks
prior to
endoscopic
surgery, had a
history of acute
infection,
antrochoanal
polyps, cystic
fibrosis, fungal
sinusitis, or
gastroesophageal
reflux disease

Interventions
Combined
budesonide
spray
(Rhinocort
Aqua) plus
LTRA
Montelukast
(Singulair)
10 mg once
daily
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OUTCOMES MEASURED
The outcomes measured in these three studies were the improvement of symptoms post
medication regimen. 10-12 Patients were asked to score their symptoms before and after the
regimen.10-12 Each study used a different symptom score report. 10-12 These symptom score
reports are Total Nasal Symptom Score (TNSS), Sino-Nasal Outcome Test (SNOT-20), and
International Classification of Sinus Disease (ICSD). 10-12 Before the patients began treatment,
intervention investigators also used the Lund-Kennedy Score System to determine polyp size, the
Lund-Mackay to determine the polyp location, or endoscopy to determine the level of
obstruction caused by the nasal polyps.10-12
Wu et al used the Lund-Kennedy scoring system prior to treatment to determine polyp
size before medical intervention. 10 Participants scored their current symptoms using the TNSS. 10
This study then compared two groups, the control group, which received combined budesonide
spray (hinocort aqua) alone and the experimental group which received combined budesonide
spray (rhinocort aqua) plus Montelukast (singulair) 10 mg once daily. 10 After this intervention,
the patients scored their symptoms using the TNSS. 10 The TNSS rates nasal congestion, runny
nose, nasal itching, sneezing, or difficulty sleeping on a scale of none, mild, moderate, and
severe. 10 The TNSS also rates the symptoms presence within 12 hours and within 2 weeks.10
Yelverton et al used the Lund-Kennedy and Lund-Mackay scoring systems to determine
the size and location of the nasal polyps. 11 Before beginning the medical regimen, the patients
scored their symptoms using SNOT-20. 11 The control group received a routine post endoscopic
sinus surgery steroid based regimen while the experimental group used the same regimen with
10mg on Montelukast as adjunct therapy. 11 They used the SNOT-20 patient symptom scoring
system again to compare their course of intervention. 11 The SNOT-20 ranks sneezing, urge to
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blow nose, runny nose, cough, post-nasal discharge, thick nasal discharge, ear fullness, dizziness,
ear pain, facial pain/pressure, difficulty sleeping, fatigue, mood changes, and disruptions with
work on a scale from very mild, mild, moderate, severe, to worst.11
Suri et all used endoscopy to determine the size and placement of the nasal polyps.12
They gave the control group oral steroid prednisolone 35mg with nasal steroid budesonide (2
metered doses).12 The experimental group was given the same regimen with additional orally
administered Montelukast 10mg.12 They used ICSD before and after the intervention. 12 ICSD
evaluates and rates patient’s symptoms of facial pain and pressure, headache, nasal blockage,
congestion, nasal discharge, anosmia, and discomfort on a 0-10 scale, 10 being the worst.12
RESULTS
In the study conducted by Wu et al, the TNSS symptom score total was used to determine
the reduction of symptoms in the experimental group compared to the control group.10 The
reduction was determined to be statistically significant.10 Before beginning their specific
treatment regimens, the mean symptom score for the control group was 6.65 and the mean TNSS
score the experimental group was 6.24.10 The mean change from baseline is greater for the
experimental group treatment than for the control group (Table 2).10 This indicates the
experimental group had overall less symptoms or a greater reduction in overall symptoms than
the control group had after the medical intervention.10 The p-value result was determined to be
statistically significant at p<0.01.10 The results from this randomized controlled trial are listed
below in Table 2.10
Table 2: Mean Change from Baseline, Wu et al10
TNSS Score Before
Treatment

TNSS Score After
Treatment

Mean Change from
Baseline
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Control Group
Experimental
Group
*p<0.01

6.65*
6.24*

5.8*
3.0*

-0.85
-3.24

In the study conducted by Yelverton et al, the SNOT-20 symptom score method showed
the difference in results between the control group and the experimental group to be statistically
significant.11 The participants were separated into groups after having completed the original
questionnaire before the medical intervention.11 After the treatment regimen, the symptom score
results for the experimental group were over four times better than the score for the control group
(Table 3).11 The p-value was determined to be statically significant at <0.001 and the confidence
interval as determined to be at 95%.11 The results are listed below in Table 3.11
Table 3: Mean change from baseline, Yelverton et al11

Control Group
Experimental
Group
*p<0.001

SNOT-20 Score Before
Treatment
29.53*
29.53*

SNOT-20 Score After
Treatment
25.61*
13.25*

Mean Change from
Baseline
-3.92
-16.28

In the study conducted by Suri et al, the ICSD symptom score total was used to determine
the reduction of symptoms in the experimental group compared to the control group as
statistically significant.12 The groups were separated and asked to complete the questionnaire
before and after the medical intervention.12 The questionnaire was filled out at 8 weeks and then
again at 12 weeks.12 After 12 weeks, the total mean change from baseline was greater for the
experimental group than for the control group.12 The p value for the 8 weeks mean change from
baseline was 0.0006 and for 12 weeks it was 0.0034.12 The results are listed below in Table 4.12
Table 4: Mean Change in Baseline, Suri et al12
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ICSD Score
Before Treatment
Control Group
Experimental
Group
*p<0.05

7.5*
7.9*

ICSD Score
After TreatmentWeek 8
5.2*
4.1*

ICSD Score
After TreatmentWeek12
5.8*
4.8*

Total Mean
Change from
Baseline
-1.7
-3.1

DISCUSSION
The three randomized controlled trials discussed in this review suggest that leukotriene
inhibitors/modifiers are effective adjunctive therapy for the management of symptoms associated
with nasal polyps.10-12 All three of these studies demonstrated statically significant reductions in
their outcomes measured along with a statistical significance threshold set at p<0.05.10-12
The randomized controlled trial by Suri et al recorded the symptom scores at 8 weeks and
then again at 12 weeks.12 At 12 weeks the symptom score worsened overall but the score for the
leukotriene inhibitor as adjunctive therapy remained lower than the score without the leukotriene
inhibitor.12 This means that although the symptoms reappeared some on week 12, the addition of
the leukotriene inhibitor, Montelukast, was still the more effective treatment.12
It is also important to note that some of the participants in the study by Yelverton et al
had endoscopic sinus surgery before participating in the randomized controlled trial.11 However,
the patients were still considered patients in the category of chronic rhinosinusitis with nasal
polyposis since they had received this diagnosis prior.11 The basis for using patients who had
received endoscopic polyp removal surgery was that patients who experience nasal polyposis are
at risk for having recurrent symptoms after their surgery.11 These patients are also at risk for
having the polyps grow back because they have predisposition to them on a on a cellular level.11
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The studies all showed statistically significant reduction of symptoms using leukotriene
inhibitor/modifiers.10-12 However, there is some question as to whether additional therapy
influences compliance. 10-12 The leukotriene inhibitor was an additional medication to the steroid
therapy, so the experimental groups received twice as many medications as the control groups.1012

In these studies, although, compliance was not listed as an issue.10-12
The Wu et al and Suri et al included baseline location and size measurements but none

followed up with the polyps after treatment. 10,11 In future studies, it would be beneficial to redo
these measurements after the interventional treatment. This would have been valuable to this
review as well, because the reduction in size of the polyps could have led to the decreased
symptoms.
These studies included very minimal reported data. All three RCTs used mean change
from baseline and p values to determine the significance of Montelukast on the associated
symptoms of nasal polyposis. 10-12 There should have been more information reported such as the
decreased size of nasal polyps for example. The studies could have benefitted from reporting
more information/ data results to make their claim that symptoms had been reduced greater in the
experimental groups. The patient reporting was excellent regarding determining significant
outcomes for patients. 10-12 However, more data to prove changes in the nasal mucosa or other
ways to represent quality of life should have been used to verify the data provided by patient
symptom scores. Lack of back up results makes the overall outcome of the review a weaker
conclusion.
CONCLUSION
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Leukotriene inhibitors/modifiers decrease the symptoms associated with nasal polyps.
They are almost always given as an adjunctive medication instead of monotherapy. The steroid
therapy which leukotriene inhibitors/modifiers are added to is effective at treating the symptoms
alone. 10-12 However, symptoms decreased even more so with the addition of a leukotriene
inhibitor/modifier. 10-12 Patients with nasal polyps will benefit from the addition of leukotriene
inhibitors/modifiers to their medical regimen. 10-12 In the future, any trials planning to determine
the effectiveness of medications on patients with nasal polyps could benefit from focusing solely
on the reduction of size of the polyps. The reduction of polyp size would reduce obstruction and
should theoretically reduce symptoms. There are still many discoveries to be made about the
development of nasal polyps as well as the most effective away to handle the symptoms that they
cause.
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